Scientech Research LLC’s NeuroSense Therapeutics NRSN Stock Holding History

Scientech Research LLC’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,584	Closed	-$10.1K	–	523
2023 Q4	$10.1K	Buy	+12,584	New	+$8.37K	0.01%	305

Other funds holding NRSN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Scientech Research LLC's NRSN Position: Q1 2024 in Review

Scientech Research LLC sold out of NeuroSense Therapeutics (NRSN) in Q1 2024, closing a stake of 12,584 shares — an estimated $10.1K sold.

Scientech Research LLC first reported a position in NRSN in Q4 2023 and held it in 1 quarter. The position peaked at $10.1K in Q4 2023. 8 funds tracked by Wall St. Rank hold NRSN as of Q1 2024.

Scientech Research LLC reported no remaining NeuroSense Therapeutics position as of Q1 2024 after selling out during the quarter.
Scientech Research LLC sold 12,584 NeuroSense Therapeutics shares in Q1 2024, an estimated $10.1K.
Scientech Research LLC first reported a position in NeuroSense Therapeutics in Q4 2023 and held it in 1 quarter.
Scientech Research LLC's NeuroSense Therapeutics position peaked at $10.1K in Q4 2023.
8 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2024.

Based on Scientech Research LLC's 13F filing for Q1 2024, filed 15 May 2024.